Abstract
Several large clinical trials for the prevention of IDDM in islet cell antibody positive first-degree relatives are planned or underway. The design of these trials rests in part on assumptions about the natural history of autoimmunity during the prediabetic period and on the likely effectiveness of the intervention being tested. At this time, most of the factors that influence the required sample size can only be roughly estimated.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Clinical Trials as Topic*
-
Diabetes Mellitus, Type 1 / drug therapy
-
Diabetes Mellitus, Type 1 / immunology
-
Diabetes Mellitus, Type 1 / prevention & control*
-
Glucose Tolerance Test
-
Humans
-
Insulin / blood
-
Insulin / therapeutic use
-
Niacinamide / therapeutic use
-
Pilot Projects
-
Prediabetic State / drug therapy
-
Prediabetic State / immunology
-
Research Design
-
Risk Factors
-
Treatment Outcome